Latest news with #NovartisPharmaceuticals
Yahoo
27-04-2025
- Health
- Yahoo
Researchers pioneer breakthrough that could change how medicine is made: 'These ... drive desired reactions forward'
Researchers at the University of Missouri have developed a chemical tool that uses "soapy" water and electricity that can reduce the cost of medicine manufacturing and enhance clean energy technology, according to Traditionally, medicine is made through electrochemistry. However, this process uses toxic solvents such as chloroform. University of Missouri associate professor Sachin Handa and graduate student Karanjeet Kaur collaborated with Novartis Pharmaceuticals to develop sustainable substances known as micelles, which are derived from naturally occurring amino acids and coconut oil. These micelles, with an appearance of soapy water, have a unique structure that can be used efficiently in electrochemical reactions without the need for toxic solvents or electrolytes. "These micelles drive desired reactions forward," explained Mizzou's Sachin Handa. "But they don't react with anything and remain stable, making them unique from ionic micelles." Because the chemical reactions are highly efficient, it could lower the cost of manufacturing certain medicines, "such as the NS5A of the Hepatitis C virus." According to Handa, it can also "be used to treat hyperproliferative, inflammatory and immunoregulatory diseases." In addition to medicine manufacturing, the micelles could also help develop clean energy technologies like hydrogen fuel. "This process, known as electrocatalysis, also plays a key role in clean energy production," Handa said. "With the same approach, hydrogen—in situ generated from water—can potentially be used as a clean fuel. Plus, we can use hydrogen to break down harmful PFAS chemicals, transforming them into useful hydrocarbons while simultaneously releasing oxygen into the air." The study was published in Angewandte Chemie International Edition. Medicine prices have risen by 15.2% year over year between 2022 and 2023, according to the Office of the Assistant Secretary for Planning and Evaluation. The advancement of this technology could lower the costs of manufacturing drugs, which could lower the costs of drugs for consumers. Should the government be able to control how we heat our homes? Definitely Only if it saves money I'm not sure No way Click your choice to see results and speak your mind. However, as senior faculty editor, Harvard Health Publishing's Robert H. Shmerling pointed out, there is no evidence of a connection between development costs for drugs and the drug price. Still, the micelles could lower toxic chemicals and the "environmental impact of traditional chemical processes" used in the production of medicine, according to the University of Missouri. And the micelles can contribute to clean energy tech. According to the U.S. Energy Information Administration, hydrogen fuel could have many uses, from fueling vehicles and power plants to energy storage and heating. Hydrogen fuel can be produced through different means, including thermal, solar, biological, and electrolytic processes, according to the U.S. Department of Energy. This new process, using the micelles from the University of Missouri and a type of electrolytic process, could help increase the production of hydrogen fuel, reducing the need for dirty energy, such as coal and gas, which contribute to planet-warming pollution and extreme weather events. Many companies are producing and testing systems of hydrogen fuel, including Honda and Hypermotive, which are collaborating on a fuel cell for vehicles. Other companies are working to test hydrogen fuel in ships and planes. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Globe and Mail
15-04-2025
- Health
- Globe and Mail
Carcinoid Tumor Syndrome Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight
DelveInsight " Carcinoid Tumor Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Carcinoid Tumor Syndrome, historical and forecasted epidemiology as well as the Carcinoid Tumor Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover which therapies are expected to grab the Carcinoid Tumor Syndrome Market Share @ Carcinoid Tumor Syndrome Market Outlook Key Takeaways from the Carcinoid Tumor Syndrome Market Report The increase in Carcinoid Tumor Syndrome Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM. As per DelveInsight analysis, the Carcinoid Tumor Syndrome Market is anticipated to witness growth at a considerable CAGR. The leading Carcinoid Tumor Syndrome Companies such as Novartis Pharmaceuticals, Crinetics Pharmaceuticals Inc., Lexicon Pharmaceuticals, Ipsen, Camurus AB, Delcath Systems Inc., INSYS Therapeutics Inc., and others. Promising Carcinoid Tumor Syndrome Pipeline Therapies such as Octreotide, Everolimus, Pasireotide (SOM230), Telotristat etiprate, Lanreotide, Isolated Perfusion, Fentanyl sublingual spray and others. Stay ahead in the Carcinoid Tumor Syndrome Therapeutics Market with DelveInsight's Strategic Report @ Carcinoid Tumor Syndrome Treatment Market Size Carcinoid Tumor Syndrome Epidemiology Segmentation in the 7MM The epidemiology section of Carcinoid Tumor Syndrome offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions. Download the report to understand which factors are driving Carcinoid Tumor Syndrome Epidemiology trends @ Carcinoid Tumor Syndrome Prevalence Carcinoid Tumor Syndrome Drugs Market The Carcinoid Tumor Syndrome Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Carcinoid Tumor Syndrome signaling in Carcinoid Tumor Syndrome are likely to uncover new therapeutic targets and further expand treatment options for patients. Carcinoid Tumor Syndrome Treatment Market Landscape The Carcinoid Tumor Syndrome treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Carcinoid Tumor Syndrome has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies. To learn more about Carcinoid Tumor Syndrome treatment guidelines, visit @ Carcinoid Tumor Syndrome Treatment Market Landscape Carcinoid Tumor Syndrome Market Outlook The report's outlook on the Carcinoid Tumor Syndrome market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Carcinoid Tumor Syndrome therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Carcinoid Tumor Syndrome drug and late-stage pipeline therapy. Carcinoid Tumor Syndrome Drugs Uptake The drug chapter of the Carcinoid Tumor Syndrome report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Carcinoid Tumor Syndrome. Major Carcinoid Tumor Syndrome Companies Novartis Pharmaceuticals, Crinetics Pharmaceuticals Inc., Lexicon Pharmaceuticals, Ipsen, Camurus AB, Delcath Systems Inc., INSYS Therapeutics Inc., and others. Learn more about the FDA-approved drugs for Carcinoid Tumor Syndrome @ Drugs for Carcinoid Tumor Syndrome Treatment Scope of the Carcinoid Tumor Syndrome Market Report • Coverage- 7MM • Study Period- 2019-2032 • Carcinoid Tumor Syndrome Companies- Novartis Pharmaceuticals, Crinetics Pharmaceuticals Inc., Lexicon Pharmaceuticals, Ipsen, Camurus AB, Delcath Systems Inc., INSYS Therapeutics Inc., and others. • Carcinoid Tumor Syndrome Pipeline Therapies- Octreotide, Everolimus, Pasireotide (SOM230), Telotristat etiprate, Lanreotide, Isolated Perfusion, Fentanyl sublingual spray and others • Carcinoid Tumor Syndrome Market Dynamics: Carcinoid Tumor Syndrome Market Drivers and Barriers • Carcinoid Tumor Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives Table of Content 1. Key Insights 2. Carcinoid Tumor Syndrome Executive Summary 3. Carcinoid Tumor Syndrome Competitive Intelligence Analysis 4. Carcinoid Tumor Syndrome: Market Overview at a Glance 5. Carcinoid Tumor Syndrome: Disease Background and Overview 6. Patient Journey 7. Carcinoid Tumor Syndrome Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 9. Carcinoid Tumor Syndrome Unmet Needs 10. Key Endpoints of Carcinoid Tumor Syndrome Treatment 11. Carcinoid Tumor Syndrome Marketed Products 12. Carcinoid Tumor Syndrome Emerging Therapies 13. Carcinoid Tumor Syndrome: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Carcinoid Tumor Syndrome Market Outlook 16. Access and Reimbursement Overview of Carcinoid Tumor Syndrome 17. KOL Views 18. Carcinoid Tumor Syndrome Market Drivers 19. Carcinoid Tumor Syndrome Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
25-02-2025
- Business
- Globe and Mail
ALK-positive Non-Small Cell Lung Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Insight' report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the ALK-positive Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ALK-positive Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the ALK-positive Non-Small Cell Lung Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ ALK-positive Non-Small Cell Lung Cancer Pipeline Outlook Key Takeaways from the ALK-positive Non-Small Cell Lung Cancer Pipeline Report In February 2025:- Novartis Pharmaceuticals:- The primary purpose of the study was to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib. Patients in the chemotherapy arm were given the option to switch to LDK378 after confirmed progressive disease (PD), while also had the choice to continue with pemetrexed treatment. In February 2025:- Hoffmann-La Roche:- A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer. In February 2025:- Takeda:- All participants will be asked to take brigatinib or alectinib at the same time each day throughout the study. For each participant eligible to continue in the study and to facilitate the remaining participants from Brigatinib-2002 (NCT03535740) to have continued treatment access, the study extension phase may be initiated for participants to continue receiving their randomized study treatment (i.e., brigatinib or alectinib) until they meet at least one of the treatment discontinuation criteria. DelveInsight's ALK-positive Non-Small Cell Lung Cancer pipeline report depicts a robust space with 6+ active players working to develop 7+ pipeline therapies for ALK-positive Non-Small Cell Lung Cancer treatment. The leading ALK-positive Non-Small Cell Lung Cancer Companies such as Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others. Promising ALK-positive Non-Small Cell Lung Cancer Therapies such as Lorlatinib, XZP-3621, X-396 (ensartinib), Crizotinib, WX-0593, SAF-189s, and others. Stay ahead with the most recent pipeline outlook for ALK-positive Non-Small Cell Lung Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ ALK-positive Non-Small Cell Lung Cancer Treatment Drugs ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Profile SY-3505: Shouyao Holdings Ficonalkib (SY-3505) is a highly potent, adenosine triphosphate-competitive, CNS-penetrant, 3rd-gen ALK TKI. In vitro kinase assay revealed that ficonalkib exhibits potent inhibition against both wild-type ALK and a diverse spectrum of mutants observed in patients resistant to 1st- and 2nd-gen ALK TKI, including L1196M, G1202R, F1174L, G1269S, and R1275Q20. The drug exhibits high kinase selectivity and has very weak inhibition on tropomyosin receptor kinase (TRK). The drug is currently being evaluated under Phase III clinical trials for the treatment of NSCLC. APG-2449: Ascentage Pharma APG-2449 is an orally available, small-molecule FAK/ALK/ROS1 TKI and the first China-developed third-generation ALK inhibitor entering clinical development. The updated results at the ASCO indicated favorable safety and promising antitumor activity in patients with NSCLC, and the preliminary efficacy observed in patients who were resistant to second-generation ALK inhibitors was particularly encouraging. APG-2449 is currently being evaluated in Phase I clinical trial for Non-Small Cell Lung Cancer. Explore groundbreaking therapies and clinical trials in the ALK-positive Non-Small Cell Lung Cancer Pipeline. Access DelveInsight's detailed report now! @ New ALK-positive Non-Small Cell Lung Cancer Drugs ALK-positive Non-Small Cell Lung Cancer Companies Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others ALK-positive Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Oral Parenteral Subcutaneous Topical Transdermal ALK-positive Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Unveil the future of ALK-positive Non-Small Cell Lung Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ ALK-positive Non-Small Cell Lung Cancer Market Drivers and Barriers Scope of the ALK-positive Non-Small Cell Lung Cancer Pipeline Report Coverage- Global ALK-positive Non-Small Cell Lung Cancer Companies- Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others. ALK-positive Non-Small Cell Lung Cancer Therapies- Lorlatinib, XZP-3621, X-396 (ensartinib), Crizotinib, WX-0593, SAF-189s, and others. ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on ALK-positive Non-Small Cell Lung Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ ALK-positive Non-Small Cell Lung Cancer Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary ALK Positive Non-Small Cell Lung Cancer : Overview Pipeline Therapeutics Therapeutic Assessment ALK Positive Non-Small Cell Lung Cancer – DelveInsight's Analytical Perspective Late Stage Products (Phase III) SY-3505: Shouyao Holdings Drug profiles in the detailed report….. Mid Stage Products (Phase II) Product Name: Company Name Drug profiles in the detailed report….. Early Stage Products (Phase I) APG-2449: Ascentage Pharma Drug profiles in the detailed report….. Preclinical Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products ALK Positive Non-Small Cell Lung Cancer - Collaborations Assessment- Licensing / Partnering / Funding ALK Positive Non-Small Cell Lung Cancer - Unmet Needs ALK Positive Non-Small Cell Lung Cancer - Market Drivers and Barriers Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
